Short description
AnaptysBio is a biotechnology company that develops antibody therapeutics based on somatic hypermutation.
Description
AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies.
This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 2005
Exited on
January 26, 2017
Went public on
January 26, 2017
Stock symbol
ANAB
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$1230 - 4560
Sign in for full access
Investors
No Way, Uh Ohhhh, Noaccess, Cannot Access, Noaccess, Noaccess, Nopepepe, Noaccess, Absolutely Noaccess, Noaccess
Sign in for full access
Founders
Andrew B. Cubitt